C
CNTX
Context Therapeutics Inc
0.3126
-0.0092-2.86%After Hours: 0.3100 -0.0026 -0.83%17:31 10/07 EDT
OPEN/PREV CLOSE0.3164/0.3218
TODAY RANGE0.3106-0.3234
VOL463.76K
MARKET CAP28.72M
52 WEEK RANGE0.2965-3.620
AVG VOL (3M)1.87M
% TURNOVER0.48%
TURNOVER--
P/E (TTM)-0.6475
% RANGE3.98%
EPS(TTM)-0.4828
P/E(FORWARD)-0.6779
P/B0.7523
BVPS0.4155
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP28.27M
SHARES OUTSTANDING91.88M
NEXT EARNINGS11/02-11/06
FREE FLOAT90.42M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·09/09 11:50
Context Therapeutics doses first patient in CT-202 trial
TipRanks·08/06 23:10
Context downgraded to Market Perform from Outperform at LifeSci Capital
TipRanks·08/06 21:26
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold
TipRanks·08/06 19:25
Context Therapeutics price target lowered to $3 from $4 at Citizens
Seeking Alpha·08/06 03:56
Context Therapeutics GAAP EPS of -$0.15
TipRanks·08/05 22:05
Context Therapeutics reports Q2 EPS (15c), consensus (9c)
TipRanks·08/05 21:21
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
TipRanks·07/31 20:31
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
TipRanks·06/26 20:31
Context Therapeutics Shareholders Approve Stock Increase and Directors
Seeking Alpha·06/20 15:00
Micron, FedEx Set To Headline Earnings Next Week
Seeking Alpha·06/19 16:00
Catalyst Watch: Micron earnings, Amazon Prime Day, and stress tests for major banks
TipRanks·06/16 13:16
Context Therapeutics price target lowered to $4 from $8 at Maxim
Same Industry
Name/Symbol
Change%
Price